

*(The A487 Trunk Road (Port Dinorwic By-pass, Gwynedd)
(Clearway) Order 1994*

Notice is hereby given that on 9th March 1994, the Secretary of State made the above Order which will come into operation on 28th March 1994.

The effect is as stated in notice 497 in *The London Gazette* No. 14452, dated 2nd September 1993.

Anyone wishing to question the validity of the Order or of any of its provisions on the grounds that it is not within the powers of the relevant section of the Act or that any requirement of that Act or any Instrument made under it has not been complied with, may within 6 weeks of 25th March 1994, apply to the High Court for this purpose.

A copy of the Order and a map may be inspected during normal office hours at the Offices of Gwynedd County Council, County Offices, Caernarfon, Gwynedd.

(485)

*(The A487 Trunk Road (Port Dinorwic By-pass, Gwynedd)
(De-Restriction) Order 1994*

Notice is hereby given that on 9th March 1994, the Secretary of State made the above Order which will come into operation on 28th March 1994.

The effect is as stated in Notice 499 in *The London Gazette* No. 14452, dated 2nd September 1993.

A copy of the Order and a map may be inspected during normal office hours at the Offices of Gwynedd County Council, County Offices, Caernarfon, Gwynedd.

(484)

SCOTTISH OFFICE

Secretary of Commissions for Scotland
St. Andrew's House, Edinburgh EH1 3DG

The QUEEN has been pleased by Warrant bearing date 25th February 1994, to direct the issue of a Commission under the Great Seal appointed to be kept and made use of in place of the Great Seal of Scotland appointing Mr. John Hamilton Scott, to be Lord-Lieutenant for the Shetland Islands Area in succession to Mr. Magnus M. Shearer.

22nd March 1994.

(526)

DEPARTMENT OF HEALTH

MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 071-273 0422 or 0425

Product Licences Authorised

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
0012/0260	May and Baker Limited (t/a Rhône-Poulenc Rorer)	Zimovane 3-75 mg Tablets	Zopiclone HSE 3-75 mg	For the short term treatment of insomnia, including difficulties in falling asleep, nocturnal awakening and early awakening, transient, situational or chronic insomnia and insomnia secondary to psychiatric disturbances, in situations where the insomnia is debilitating or is causing severe distress for the patient. POM	13th December 1993
0025/0293	Merck Sharp and Dohme Limited (t/a Thomas Morson Pharmaceuticals)	Pneumovax II Vaccine	Pneumococcal Polysaccharide Type 1(1): Danish (US) Numbering HSE 25-0 µg Pneumococcal Polysaccharide Type 2 (2) HSE 25-0 µg Pneumococcal Polysaccharide Type 3 (3) HSE 25-0 µg Pneumococcal Polysaccharide Type 4 (4) HSE 25-0 µg Pneumococcal Polysaccharide Type 5 (5) HSE 25-0 µg Pneumococcal Polysaccharide Type 6B (26) HSE 25-0 µg Pneumococcal Polysaccharide Type 7F (51) HSE 25-0 µg Pneumococcal Polysaccharide Type 8 (8) HSE 25-0 µg Pneumococcal Polysaccharide Type 9N (9) HSE 25-0 µg Pneumococcal Polysaccharide Type 9V (68) HSE 25-0 µg Pneumococcal Polysaccharide Type 10A (34) HSE 25-0 µg Pneumococcal Polysaccharide Type 11A (43) HSE 25-0 µg Pneumococcal Polysaccharide Type 12F (12) HSE 25-0 µg Pneumococcal Polysaccharide Type 14 (14) HSE 25-0 µg Pneumococcal Polysaccharide Type 15B (54) HSE 25-0 µg Pneumococcal Polysaccharide Type 17F (17) HSE 25-0 µg Pneumococcal Polysaccharide Type 18C (56) HSE 25-0 µg Pneumococcal Polysaccharide Type 19A (57) HSE 25-0 µg Pneumococcal Polysaccharide Type 19F (19) HSE 25-0 µg Pneumococcal Polysaccharide Type 20 (20) HSE 25-0 µg Pneumococcal Polysaccharide Type 22F (22) HSE 25-0 µg Pneumococcal Polysaccharide Type 23F (23) HSE 25-0 µg Pneumococcal Polysaccharide Type 33F (70) HSE 25-0 µg	Pneumovax II is a pneumococcal vaccine indicated for immunisation against pneumococcal disease caused by those pneumococcal types included in the vaccine. It will not immunise against capsular types of pneumococcus other than those contained in the vaccine. It should be considered for all persons two years of age or older in whom there is an increased risk of morbidity and mortality from pneumococcal pneumonia. Pneumovax II may not be effective in preventing infection resulting from basilar skull fracture or from external communication with cerebrospinal fluid. POM	3rd December 1993
0025/0295	Merck Sharp and Dohme Limited	H-B-VAX II Paediatric	Per 0.5 ml Dose Hepatitis B Surface Antigen 5-0 µg	H-B-VAX II is indicated for immunisation against infection	14th December 1993